| Prev Close | 244.77 |
| Day Low/High | 242.96 / 247.66 |
| 52 Wk Low/High | 198.64 / 258.45 |
Amgen Inc. (AMGN)
247.50
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 534.20B |
| Market Cap | 130.76B |
| P/E Ratio | 20.43 |
| Div & Yield | N.A. (N.A) |
Latest News
7 Best Buys in Biotech and Drug Development
Recently poor sector performance is creating opportunity for long-term investors.
The Selling in Growth Names Is Gaining Some Momentum
It's always surprising how quickly stocks can reverse for no real reason.
Amgen Gaps Higher on Mixed Numbers, Share Buyback
Let's review the charts and indicators.
Week in Review, Oil, Jobs Data, Peloton Suitors, Uber Earnings Preview
It was a solid, though volatile week for U.S. stocks.
Amgen's Charts Continue to Strengthen
This rally could surprise on the upside.
Shares of Amgen Are Finally Beginning to Turn Around
We have a new price target for now.
5 Reasons to Bet on Biotech
Small-cap biotech names are seeing dramatic, widespread declines, creating a liquidation sale for investors.
Money Is Moving, Midcap Opportunity? Fed Meeting, Coal, Earnings Chatter, Rivian
How far behind the large-cap indexes the S&P 400 and S&P 600 really are is astounding.
'Achieve' High Returns With These 3 Dividend Growth Stocks
These names are among our favorite Dividend Achievers, those companies with at least a decade of dividend growth.
Black Monday Recollections, Bitcoin ETF Launch, Fed Numbers, FDA, Disney's Dip
While cryptocurrencies are indeed an asset class, and they are divisible, they do not serve as a medium of exchange, and remain unproven as a store of value.
3 Big Pharma Buys for Dividend Investors
In a market with elevated valuations and low yields, we see pharmaceutical stocks as a respite from both.
Market on Eggshells, Masking Up, ISM, Pfizer and Moderna Just Getting Started
Doesn't the Fed now have to taper asset purchases simply to avoid becoming an even greater force in these markets?
How Now, Dow Jones?
The Dow Jones Industrial Average is being dragged down by Amgen , Microsoft and Boeing . Â
My Beautiful Balloon, Unmasking the Market, Crypto Risk, Preparing for Powell
With the economy apparently growing robustly, the Fed has to watch how the president's plans play out in terms of the size and scope of deficit spending.
The Pullback Is on Schedule
Now, let's look at 2000, and see if we can spot any similarities....
Amgen Looks Ready for an Upside Breakout
Traders could go long at current levels risking below $240 for now.
Jim Cramer: Robbing Peter to Pay Paul
Let's review this Archegos drama and some lessons from this fickle market.
A Market No-Doubter, Vaccine Milestone, GDP Green Shoots, Inovio, Amazon, Google
The fact is that even if there is some compromise, the next fiscal stimulus package will be closer to $1.9 trillion than $600 billion.
Jim Cramer: Here's Why the Market Is Cheering Georgia's Results
The fears of what would happen from Democratic wins in Georgia's race failed to pan out, aside from tech taking a few hits. Here's what's happening instead and why.
Real Money Post Industrial Average Bests Most Major Indexes in 2020
As we enter the new year, there's little time to reflect on RMPIA's strong performance. Now, it's all eyes on the 12 months ahead of us.
My 10 'No Doubt' Predictions for 2021
From Amazon to Zoom, here are my prognostications and best ideas for the new year.
Let's See How These Dividend Gifts Stack Up
Let's compare several dividend increases in time for the holidays -- and see who wins the 'derby.'
Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week
These names are displaying technical deterioration.
A 3% Dividend Yield With Growth in the Pipeline
With four consecutive flat quarterly dividends, this pharmaceutical name could be on the verge of another hefty raise.
Real Money Post Industrial Average Rises 21% Year to Date
The average declined in October, but it was less than that hit took by the major indexes.
Surviving in This Environment, Shaky Recovery, Lilly and Pfizer Setbacks
The 'work from home' or 'economic lockdown' trade is close to being back on.
